ClinicalTrials.gg
CompletedNCT02834442Updated Jul 25, 2017

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects

A Phase 1 interventional study of MT-7117 and Placebo in Healthy, sponsored by Mitsubishi Tanabe Pharma Corporation. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-25.

Sponsored by Mitsubishi Tanabe Pharma Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of MT-7117 in healthy subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Mitsubishi Tanabe Pharma Corporation is the lead sponsor of 40 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy and free from illness or disease
  • Male or female subjects aged 18 to 55 years or elderly male subjects aged ≥65
  • A body weight of ≥60 kg for males and ≥50 kg for females, and a ranging from 18 to 30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Participated in more than three clinical studies involving administration of an IMP in the previous year, or any study within 12 weeks
  • endocrine, thyroid, hepatic, respiratory, gastro intestinal, renal, cardiovascular or skin disease, or history of any significant psychiatric/psychotic illness disorder
  • Clinically relevant abnormal medical history, physical findings or laboratory values
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
144 participants (actual)

Study arms

  • Experimental
    Single ascending dose, MT-7117 or Placebo

    Drug: MT-7117 · Drug: Placebo

  • Experimental
    Multiple ascending dose, MT-7117 or Placebo

    Drug: MT-7117 · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability as measured by number of participants with adverse events

    Time frame: up to Day56

  2. Safety and Tolerability as measured by vital signs

    Time frame: up to Day56

  3. Safety and Tolerability as measured by physical examination

    Time frame: up to Day56

  4. Safety and Tolerability as measured by ECG

    Time frame: up to Day21

  5. Safety and Tolerability as measured by laboratory safety assessments

    Time frame: up to Day21

Secondary outcomes

  1. Maximum plasma concentration (Cmax)

    Time frame: 96 hours post dose

  2. Area under the plasma concentration-time curve (AUC)

    Time frame: 96 hours post dose

  3. Time to maximum plasma concentration (Tmax)

    Time frame: 96 hours post dose

  4. Apparent elimination half-life in plasma

    Time frame: 96 hours post dose

07

Study locations

1 site
  • Investigational center
    United Kingdom, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2016, a primary completion of Jun 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2016
First posted
Jul 15, 2016
Start
Jul 2016
Primary completionActual
Jun 2017
CompletionActual
Jun 2017
Last update
Jul 25, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02834442
Responsible party
Sponsor
First posted
Jul 15, 2016
Start date
Jul 2016
Primary completion
Jun 2017
Completion
Jun 2017
Last update
Jul 25, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dersimelagon

Start the discussion